Robert L Walsky - JoVE Visualize

Showing results (11-20 of 25) with videos related to

Pageof 3

Sort By:

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 4, 2015

Pharmacokinetics of the natural antibiotic negamycinJian Guo, Eric W Miele, April Chen, et al.

Antimicrobial Agents and Chemotherapy|November 26, 2008

In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafunginBharat D Damle, James A Dowell, Robert L Walsky, et al.

The Annals of Pharmacotherapy|December 22, 2005

Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolismRobert A Moller, Jeannine M Fisher, Ann E Taylor, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2008

Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drugJonathan N Bauman, Kosea S Frederick, Aarti Sawant, et al.

British Journal of Clinical Pharmacology|January 12, 2012

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro dataPankaj Gupta, Christine Alvey, Rong Wang, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012

Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 17, 2014

Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide)Elaine Tseng, Robert L Walsky, Ricardo A Luzietti, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 22, 2011

Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitusAmit S Kalgutkar, Meera Tugnait, Tong Zhu, et al.

Journal of Clinical Pharmacology|October 27, 2007

Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro studyAaron H Burstein, David J Clark, Melissa O'Gorman, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012

Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.

Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:

Pageof 3

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 4, 2015

Pharmacokinetics of the natural antibiotic negamycinJian Guo, Eric W Miele, April Chen, et al.

Antimicrobial Agents and Chemotherapy|November 26, 2008

In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafunginBharat D Damle, James A Dowell, Robert L Walsky, et al.

The Annals of Pharmacotherapy|December 22, 2005

Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolismRobert A Moller, Jeannine M Fisher, Ann E Taylor, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 12, 2008

Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drugJonathan N Bauman, Kosea S Frederick, Aarti Sawant, et al.

British Journal of Clinical Pharmacology|January 12, 2012

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro dataPankaj Gupta, Christine Alvey, Rong Wang, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012

Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 17, 2014

Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide)Elaine Tseng, Robert L Walsky, Ricardo A Luzietti, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 22, 2011

Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitusAmit S Kalgutkar, Meera Tugnait, Tong Zhu, et al.

Journal of Clinical Pharmacology|October 27, 2007

Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro studyAaron H Burstein, David J Clark, Melissa O'Gorman, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012

Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsRobert L Walsky, R Scott Obach, Ruth Hyland, et al.

Pageof 3